Nexien Biopharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Nexien BioPharma reports its Q3 2025 results, highlighting a net loss and ongoing concerns about the company's ability to continue as a going concern without additional funding.
OTC.Pink
Nexien BioPharma's Q2 2025 report reveals a net loss and continued concerns about the company's ability to continue as a going concern without additional funding.
OTC.Pink
Nexien BioPharma's Q3 2024 report reveals a reduced net loss compared to the previous year, but the company faces significant financial challenges and going concern uncertainty.
OTC.Pink
Nexien BioPharma reports a net loss of $152,599 for the nine months ended March 31, 2024, highlighting ongoing financial challenges and the need for additional capital.
OTC.Pink
Nexien BioPharma's Q2 2024 report reveals a reduced net loss compared to the previous year, but the company faces significant financial challenges and going concern uncertainty.